SCHEMBL19788596

SCHEMBL19788596

CC(c1cc2c(Cl)cccc2nc1Cl)N1C(=O)c2ccccc2C1O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.39
LMNA P02545 1/20 0.39
RAB9A P51151 4/20 0.36
ALDH1A1 P00352 3/20 0.36
HSD17B10 Q99714 1/20 0.36
NPC1 O15118 3/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
PKM P14618 2/20 0.35
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
ATM Q13315 1/20 0.34
KCNA5 P22460 1/20 0.34
KDM4E B2RXH2 2/20 0.33
TP53 P04637 2/20 0.33
GAA P10253 1/20 0.33
PDE3B Q13370 1/20 0.33
PDE3A Q14432 1/20 0.33
STAT3 P40763 1/20 0.33
STAT1 P42224 1/20 0.33
FFAR1 O14842 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20072535 0.84 HPGD (0.40) HPGDLMNARAB9AALDH1A1HSD17B10
SCHEMBL20072599 0.84 CYP3A4 (0.39) HPGDLMNAALDH1A1HSD17B10MEN1
SCHEMBL4180794 0.80 LMNA (0.39) LMNAMEN1KMT2AATMKDM4E
SCHEMBL21705933 0.77 HPGD (0.37) HPGDLMNARAB9AALDH1A1HSD17B10
SCHEMBL20072552 0.75 HPGD (0.37) HPGDLMNARAB9AALDH1A1HSD17B10
SCHEMBL21705930 0.74 HPGD (0.36) HPGDLMNARAB9AALDH1A1HSD17B10
SCHEMBL19788574 0.73 HPGD (0.38) HPGDLMNARAB9AALDH1A1HSD17B10
SCHEMBL21705934 0.72 ATM (0.35) HPGDLMNARAB9AALDH1A1HSD17B10
SCHEMBL19788597 0.72 PIK3CD (0.36) HPGDLMNARAB9AALDH1A1HSD17B10
SCHEMBL21705318 0.71 HPGD (0.36) HPGDLMNARAB9AALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200048265-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2020-02-13 US disclosed
US-9873701-B2 Heterocyclic compounds and their uses AMGEN INC. (US) 2018-01-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200048265-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES MCL1, BCL9, MALT1 HPGD 2389/4885LMNA 2309/4885RAB9A 2240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.